CTX130
- Generic Name
- CTX130
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
- Associated Conditions
- -
- Associated Therapies
- -
Renal Cancer Clinical Trial Pipeline Appears Robust With
DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies
DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech, Allogene Therapeutics, and Merck & Co. Inc. Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath